AtriCure, Inc. (ATRC) FY2026 Q2 P&L / Income Statement

AtriCure, Inc. (ATRC) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue

153,604,000 US dollars

Cost of revenue

34,975,000 US dollars

Gross profit

118,629,000 US dollars

Total operating expenses

108,964,000 US dollars

Income (loss) from operations

9,665,000 US dollars

Other income (expense), net (calculated)

negative 239,000 US dollars

Income (loss) before income tax expense

9,426,000 US dollars

Income tax expense

471,000 US dollars

Net income (loss)

8,955,000 US dollars

Appendage management - UNITED STATES

51,614,000 US dollars

Minimally invasive ablation - UNITED STATES

6,031,000 US dollars

Open ablation - UNITED STATES

40,885,000 US dollars

Pain management - UNITED STATES

27,058,000 US dollars

Undisclosed (calculated)

28,016,000 US dollars

Selling, general and administrative expenses

82,562,000 US dollars

Research and development expenses

26,402,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.